(R)-2-(1-phenylethyl)-4,5,6,7-tetrafluoro-1H-isoindole-1,3-dione | 182690-77-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: (R)-2-(1-phenylethyl)-4,5,6,7-tetrafluoro-1H-isoindole-1,3-dione
• 英文别名: 4,5,6,7-tetrafluoro-2-[(1R)-1-phenylethyl]isoindole-1,3-dione
• CAS: 182690-77-3
• 化学式: C₁₆H₉F₄NO₂
• 分子量: 323.247
• InChiKey: WZQOJDGLRKJWCO-SSDOTTSWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  37.4
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  3,4,5,6-四氟苯酐 、 R(+)-alpha-甲基苄胺 在 silica gel 、 二氯甲烷 、 甲醇 、 ethyl acetate n-hexane 作用下， 以 氯仿 为溶剂， 反应 2.0h， 以to obtain 210 mg of the desired product as colorless needles的产率得到(R)-2-(1-phenylethyl)-4,5,6,7-tetrafluoro-1H-isoindole-1,3-dione
  参考文献：
  名称：

  Pharmaceutical composition

  摘要：

  它是为了提供一种环内酰亚胺衍生物，该衍生物可用作药物组合物的活性成分。该药物组合物包括由通式（I）表示的环内酰亚胺衍生物，其中Q1是单键，-CH2-，-O-，-S-或-NH-，Q2和Q3每个是-C（O）-，-C（S）-或-CH2-，但至少有一个是-C（O）-或-C（S）-，Z是单键或低级脂肪二基基团，R是芳基基团，可以被取代或环烷基团，可以被取代，X是硝基基团，可以酰化的氨基基团，氰基，三氟甲基基团，羟基，卤素原子，烷基，烷氧基或烷硫基，m是0到4的整数，当m为2或以上时，X可以相同或不同，或其盐。

  公开号：

  US06515129B1

文献信息

• Medicinal composition
  申请人：Ishihara Sangyo Kaisha Ltd.

  公开号：US06429212B1

  公开（公告）日：2002-08-06

  It is to provide a cyclic imide derivative which is useful as an active ingredient of a pharmaceutical composition. A pharmaceutical composition which comprises, a cyclic imide derivative represented by the general formula (I): wherein Q1 is a single bond, —CH2—, —O—, —S— or —NH—, each of Q2 and Q3 is —C(O)—, —C(S)— or —CH2—, provided that at least one of Q2 and Q3 is —C(O)— or —C(S)—, Z is a single bond or a lower alkanediyl group, R is an aryl group which may be substituted or a cycloalkyl group which may be substituted, X is a nitro group, an amino group which may be acylated, a cyano group, a trifluoromethyl group, a hydroxyl group, a halogen atom, an alkyl group, an alkoxy group or an alkylthio group, m is an integer of from 0 to 4, and when m is 2 or above, X may be the same or different, or its salt.

  提供的是一种环状亚胺衍生物，它作为药物组合物的有效成分很有用。所述药物组合物包含由通式(I)表示的环状亚胺衍生物： 其中Q1是单键、-CH2-、-O-、-S-或-NH-，Q2和Q3每个是-C(O)-、-C(S)-或-CH2-，前提是Q2和Q3中至少有一个是-C(O)-或-C(S)-，Z是单键或低级脂肪二烯基团，R是可以被取代的芳基团或可以被取代的环烷基团，X是硝基团、可能被酰化的氨基团、氰基团、三氟甲基团、羟基团、卤素原子、烷基团、烷氧基团或烷硫基团，m是从0到4的整数，当m为2或以上时，X可以是相同的或不同的，或其盐。
• Pharmaceutical composition
  申请人：Ishihara Sangyo Kaisha Ltd.

  公开号：US06515129B1

  公开（公告）日：2003-02-04

  It is to provide a cyclic imide derivative which is useful as an active ingredient of a pharmaceutical composition. A pharmaceutical composition which comprises, a cyclic imide derivative represented by the general formula (I): wherein Q1 is a single bond, —CH2—, —O—, —S— or —NH—, each of Q2 and Q3 is —C(O)—, —C(S)— or —CH2—, provided that at least one of Q2 and Q3 is —C(O)— or —C(S)—, Z is a single bond or a lower alkanediyl group, R is an aryl group which may be substituted or a cycloalkyl group which may be substituted, X is a nitro group, an amino group which may be acylated, a cyano group, a trifluoromethyl group, a hydroxyl group, a halogen atom, an alkyl group, an alkoxy group or an alkylthio group, m is an integer of from 0 to 4, and when m is 2 or above, X may be the same or different, or its salt.

  它是为了提供一种环内酰亚胺衍生物，该衍生物可用作药物组合物的活性成分。该药物组合物包括由通式（I）表示的环内酰亚胺衍生物，其中Q1是单键，-CH2-，-O-，-S-或-NH-，Q2和Q3每个是-C（O）-，-C（S）-或-CH2-，但至少有一个是-C（O）-或-C（S）-，Z是单键或低级脂肪二基基团，R是芳基基团，可以被取代或环烷基团，可以被取代，X是硝基基团，可以酰化的氨基基团，氰基，三氟甲基基团，羟基，卤素原子，烷基，烷氧基或烷硫基，m是0到4的整数，当m为2或以上时，X可以相同或不同，或其盐。
• Enantio-dependence of inducer-specific bidirectional regulation of tumor necrosis factor (TNF)-alpha production: Potent TNF-α production inhibitors
  作者：Hiroyuki Miyachi、Akihiko Azuma、Erika Hioki、Shigeo Iwasaki、Yuichi Hashimoto

  DOI：10.1016/0960-894x(96)00409-x

  日期：1996.10

  In optically active phthalimide analogs of thalidomide, the inducer-specific TNF-alpha production-enhancing and -inhibiting activities are separated. This implies that the target molecules of the two activities are different. Copyright (C) 1996 Elsevier Science Ltd
• Potent novel nonsteroidal androgen antagonists with a phthalimide skeleton
  作者：Hiroyuki Miyachi、Akihiko Azuma、Takuya Kitamoto、Kozue Hayashi、Shigeaki Kato、Masafumi Koga、Bunzo Sato、Yuichi Hashimoto

  DOI：10.1016/s0960-894x(97)00249-7

  日期：1997.6

  Anti-androgenic activity of various phthalimide analogs was evaluated based on inhibition of androgen-induced activation of nuclear androgen receptor (CAT assay) and on growth inhibition of the androgen-dependent clonal cell Line SC-3. Some compounds showed very potent androgen-antagonistic activity. (C) 1997 Elsevier Science Ltd.
• US6429212B1
  申请人：——

  公开号：US6429212B1

  公开（公告）日：2002-08-06